Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 20

Sort by

Sort Order Select

Journal Articles

Polatuzumab vedotin in previously untreated DLBCL: an Asia subpopulation analysis from the phase 3 POLARIX trial

Blood (2023) 141 (16): 1971–1981.

https://doi.org/10.1182/blood.2022017734

Published: 2023

Includes: Supplemental data

Journal Articles

Polatuzumab Vedotin Plus Bendamustine and Rituximab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL): Final Results of a Phase Ib/II Randomized Study and Single-Arm Extension (Ext) Study

Laurie H. Sehn, Mark Hertzberg, Stephen Opat, Alex F. Herrera, Sarit Assouline, Christopher R. Flowers, Tae Min Kim, Andrew K. McMillan, Muhit Özcan, Violaine Safar, Gilles Salles, Jamie Hirata, Annie Yang, Lisa Musick, Matthew J. Matasar

Blood (2022) 140 (Supplement 1): 9464–9467.

https://doi.org/10.1182/blood-2022-157679

Published: 2022

Journal Articles

Risk Profiling of Patients with Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL) By Measuring Circulating Tumor DNA (ctDNA): Results from the POLARIX Study

Blood (2022) 140 (Supplement 1): 1297–1300.

https://doi.org/10.1182/blood-2022-157559

Published: 2022

Journal Articles

A Phase Ib/II Study of Polatuzumab Vedotin Plus Obinutuzumab and Lenalidomide in Patients with Relapsed/Refractory Follicular Lymphoma: Final Analysis and Progression-Free Survival Update

Catherine S. Diefenbach, Brad S. Kahl, Lalita Banerjee, Andrew K. McMillan, Fiona Miall, Javier Briones, Raul Cordoba, John M. Burke, Jamie Hirata, Sunil Sharma, Lisa Musick, Pau Abrisqueta Costa

Blood (2022) 140 (Supplement 1): 2286–2288.

https://doi.org/10.1182/blood-2022-157720

Published: 2022

Journal Articles

Epidemiological Impact of Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin and Prednisone (Pola-R-CHP) Use in Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL) in Terms of Second Line (2L) Treatment: An Ad Hoc Analysis from the POLARIX Study

Frédéric Boissard, Hervé Tilly, Georg Lenz, Graham P. Collins, Antonio Pinto, Laurie H. Sehn, Gilles Salles, Mathilde Roussel, Leonardo Simonella, Rodrigo Ho, Jamie Hirata, Calvin Lee, Anthony Masaquel, Aino Launonen

Blood (2022) 140 (Supplement 1): 6645–6647.

https://doi.org/10.1182/blood-2022-157904

Published: 2022

Journal Articles

Health-Related Quality of Life (HRQoL) in Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Treated with Polatuzumab Vedotin, Rituximab, Cyclophosphamide, Doxorubicin and Prednisone (Pola-R-CHP) Versus Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (R-CHOP) in the Phase III POLARIX Study

Blood (2022) 140 (Supplement 1): 6623–6626.

https://doi.org/10.1182/blood-2022-157761

Published: 2022

Journal Articles

The POLARIX Study: Polatuzumab Vedotin with Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (pola-R-CHP) Versus Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (R-CHOP) Therapy in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma

Blood (2021) 138 (Supplement 2): LBA-1.

https://doi.org/10.1182/blood-2021-154729

Published: 2021

Journal Articles

POLARGO: Randomized Phase III Study of Polatuzumab Vedotin Plus Rituximab, Gemcitabine, and Oxaliplatin in Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Matthew J. Matasar, Corinne Haioun, Juan-Manuel Sancho, Andreas Viardot, Jamie Hirata, Thomas Perretti, Lisa Musick, Andrew K McMillan

Blood (2021) 138 (Supplement 1): 3568.

https://doi.org/10.1182/blood-2021-145857

Published: 2021

Journal Articles

Polatuzumab Vedotin Plus Bendamustine and Rituximab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Updated Results of a Phase Ib/II Randomized Study and Preliminary Results of a Single-Arm Extension

Laurie H. Sehn, MDMPH, Mark Hertzberg, Stephen Opat, MBBS (Hons), FRACP, FRCPA, Alex F. Herrera, MD, Sarit E Assouline, MD MSc, Christopher Flowers, MDMS, Tae Min Kim, MD PhD, Andrew McMillan, Muhit Ozcan, Violaine Safar, Gilles Salles, MD PhD, Lisa Musick, Jamie Hirata, YiMeng Chang, Grace Ku, Matthew J Matasar, MD

Blood (2020) 136 (Supplement 1): 17–19.

https://doi.org/10.1182/blood-2020-137078

Published: 2020

Journal Articles

Polatuzumab Vedotin Plus Venetoclax with Rituximab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Primary Efficacy Analysis of a Phase Ib/II Study

Giuseppe Gritti, MD PhD, Paula Marlton, MBBS FRACP FRCPA, Tycel J. Phillips, MD, Christopher Arthur, Rajat Bannerji, MDPhD, Paolo Corradini, Anna Johnston, John F. Seymour, Sam Yuen, MBBS, FRACP, FRCPA, Jamie Hirata, Lisa Musick, Sourish Saha, Brandon Croft, Christopher Flowers, MDMS

Blood (2020) 136 (Supplement 1): 45–47.

https://doi.org/10.1182/blood-2020-136361

Published: 2020

Journal Articles

Polatuzumab Vedotin Plus Obinutuzumab and Lenalidomide in Patients With Relapsed/Refractory Follicular Lymphoma: Primary Analysis of the Full Efficacy Population in a Phase Ib/II Trial

Catherine Diefenbach, MD, Brad S. Kahl, MD, Lalita Banerjee, FRCPath, Andrew K McMillan, FRCP, Fiona Miall, MD FRCPath, MRCP, BMBS, Javier Briones, MD PhD, Raul Cordoba, MD PhD, Jamie Hirata, PharmD, YiMeng Chang, MSc, Lisa Musick, PharmD, Pau Abrisqueta, MD PhD

Blood (2019) 134 (Supplement_1): 126.

https://doi.org/10.1182/blood-2019-123669

Published: 2019

Journal Articles

Polatuzumab Vedotin Plus Bendamustine with Rituximab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Updated Results of a Phase Ib/II Randomized Study

Laurie H Sehn, MD, Matthew J Matasar, MD, Christopher R. Flowers, MD MS, Manali Kamdar, MD MD, Andrew K McMillan, FRCP, Mark Hertzberg, MD MBBS, PhD, Sarit Assouline, MD, Tae Min Kim, MD PhD, Won Seog Kim, MD PhD, Muhit Ozcan, MD, Brandon Croft, PharmD, Jamie Hirata, PharmD, Ji Cheng, PhD, Grace Ku, MD, Alex F. Herrera, MD

Blood (2019) 134 (Supplement_1): 4081.

https://doi.org/10.1182/blood-2019-123449

Published: 2019

Journal Articles

Durable remissions with obinutuzumab-based chemoimmunotherapy: long-term follow-up of the phase 1b GALTON trial in CLL

Jennifer R. Brown, Susan O’Brien, C. Daniel Kingsley, Herbert Eradat, John M. Pagel, Jamie Hirata, Tammy McIver, Rodica Morariu-Zamfir, Thomas J. Kipps

Blood (2019) 133 (9): 990–992.

https://doi.org/10.1182/blood-2018-06-857714

Published: 2019

Journal Articles

Polatuzumab Vedotin Combined with Obinutuzumab for Patients with Relapsed or Refractory Non-Hodgkin Lymphoma: Preliminary Safety and Clinical Activity of a Phase Ib/II Study

Tycel Phillips, MD, Mark Brunvand, MD, Andy Chen, MD PhD, Oliver Press, MD PhD, James Essell, MD, Annalisa Chiappella, MD, Catherine Diefenbach, MD, Surai Jones, MS Biostat, Jamie Hirata, PharmD, Ian W. Flinn, MD PhD

Blood (2016) 128 (22): 622.

https://doi.org/10.1182/blood.V128.22.622.622

Published: 2016

Journal Articles

Randomized phase 2 study of obinutuzumab monotherapy in symptomatic, previously untreated chronic lymphocytic leukemia

John C. Byrd, Joseph M. Flynn, Thomas J. Kipps, Michael Boxer, Kathryn S. Kolibaba, David J. Carlile, Guenter Fingerle-Rowson, Nicola Tyson, Jamie Hirata, Jeff P. Sharman

Blood (2016) 127 (1): 79–86.

https://doi.org/10.1182/blood-2015-03-634394

Published: 2016

Journal Articles

Polatuzumab Vedotin Combined with Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) for Patients with Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL): Preliminary Results of a Phase Ib Dose-Escalation

Nancy L. Bartlett, Andy I Chen, MD PhD, Kathryn S. Kolibaba, Thierry Lamy, MDPhD, Surai Jones, Jamie Hirata, Jeff P. Sharman, MD

Blood (2015) 126 (23): 2726.

https://doi.org/10.1182/blood.V126.23.2726.2726

Published: 2015

Journal Articles

Exposure-Response Analysis to Assist Selection of Dose and Treatment Duration for Polatuzumab Vedotin As a Single Agent or in Combination with Rituximab for the Treatment of B-Cell Lymphoma

Dan Lu, Jin Yan Jin, Leonid Gibiansky, William R. Gillespie, Priya Agarwal, Cheryl Jones, Yu-Waye Chu, Michael K. Wenger, Jamie Hirata, Chunze Li, Sandhya Girish

Blood (2015) 126 (23): 1525.

https://doi.org/10.1182/blood.V126.23.1525.1525

Published: 2015

Journal Articles

Obinutuzumab plus fludarabine/cyclophosphamide or bendamustine in the initial therapy of CLL patients: the phase 1b GALTON trial

Jennifer R. Brown, Susan O’Brien, C. Daniel Kingsley, Herbert Eradat, John M. Pagel, James Lymp, Jamie Hirata, Thomas J. Kipps

Blood (2015) 125 (18): 2779–2785.

https://doi.org/10.1182/blood-2014-12-613570

Published: 2015

Journal Articles

Safety and Efficacy Of Obinutuzumab (GA101) With Fludarabine/Cyclophosphamide (G-FC) Or Bendamustine (G-B) In The Initial Therapy Of Patients With Chronic Lymphocytic Leukemia (CLL): Results From The Phase 1b Galton Trial (GAO4779g)

Jennifer R Brown, MD, PhD, Susan O'Brien, MD, C Daniel Kingsley, MD, FACP, Herbert Eradat, MS, MD, John M. Pagel, MD, PhD, James Lymp, PhD, Jamie Hirata, PharmD, Thomas J. Kipps, MD, PhD

Blood (2013) 122 (21): 523.

https://doi.org/10.1182/blood.V122.21.523.523

Published: 2013

Journal Articles

Racial Disparities in Disease Presentation, Treatment, and Response Rates of Follicular Lymphoma (FL) in the United States (US): Report From the National LymphoCare Study (NLCS).

Chadi Nabhan, MD, FACP, Michael Taylor, PharmD, PhD, Jamie Hirata, Ming Lin, Benjamin Parsons, Christopher R. Flowers, MD

Blood (2009) 114 (22): 1381.

https://doi.org/10.1182/blood.V114.22.1381.1381

Published: 2009

NARROW

Polatuzumab vedotin in previously untreated DLBCL: an Asia subpopulation analysis from the phase 3 POLARIX trial

Polatuzumab Vedotin Plus Bendamustine and Rituximab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL): Final Results of a Phase Ib/II Randomized Study and Single-Arm Extension (Ext) Study

Risk Profiling of Patients with Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL) By Measuring Circulating Tumor DNA (ctDNA): Results from the POLARIX Study

A Phase Ib/II Study of Polatuzumab Vedotin Plus Obinutuzumab and Lenalidomide in Patients with Relapsed/Refractory Follicular Lymphoma: Final Analysis and Progression-Free Survival Update

Epidemiological Impact of Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin and Prednisone (Pola-R-CHP) Use in Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL) in Terms of Second Line (2L) Treatment: An Ad Hoc Analysis from the POLARIX Study

The POLARIX Study: Polatuzumab Vedotin with Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (pola-R-CHP) Versus Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (R-CHOP) Therapy in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma

POLARGO: Randomized Phase III Study of Polatuzumab Vedotin Plus Rituximab, Gemcitabine, and Oxaliplatin in Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Polatuzumab Vedotin Plus Bendamustine and Rituximab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Updated Results of a Phase Ib/II Randomized Study and Preliminary Results of a Single-Arm Extension

Polatuzumab Vedotin Plus Venetoclax with Rituximab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Primary Efficacy Analysis of a Phase Ib/II Study

Polatuzumab Vedotin Plus Obinutuzumab and Lenalidomide in Patients With Relapsed/Refractory Follicular Lymphoma: Primary Analysis of the Full Efficacy Population in a Phase Ib/II Trial

Polatuzumab Vedotin Plus Bendamustine with Rituximab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Updated Results of a Phase Ib/II Randomized Study

Durable remissions with obinutuzumab-based chemoimmunotherapy: long-term follow-up of the phase 1b GALTON trial in CLL

Polatuzumab Vedotin Combined with Obinutuzumab for Patients with Relapsed or Refractory Non-Hodgkin Lymphoma: Preliminary Safety and Clinical Activity of a Phase Ib/II Study

Randomized phase 2 study of obinutuzumab monotherapy in symptomatic, previously untreated chronic lymphocytic leukemia

Polatuzumab Vedotin Combined with Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) for Patients with Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL): Preliminary Results of a Phase Ib Dose-Escalation

Exposure-Response Analysis to Assist Selection of Dose and Treatment Duration for Polatuzumab Vedotin As a Single Agent or in Combination with Rituximab for the Treatment of B-Cell Lymphoma

Obinutuzumab plus fludarabine/cyclophosphamide or bendamustine in the initial therapy of CLL patients: the phase 1b GALTON trial

Safety and Efficacy Of Obinutuzumab (GA101) With Fludarabine/Cyclophosphamide (G-FC) Or Bendamustine (G-B) In The Initial Therapy Of Patients With Chronic Lymphocytic Leukemia (CLL): Results From The Phase 1b Galton Trial (GAO4779g)

Racial Disparities in Disease Presentation, Treatment, and Response Rates of Follicular Lymphoma (FL) in the United States (US): Report From the National LymphoCare Study (NLCS).

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only